Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

Biotechnology

Mammoth Biosciences

Trevor Martin

Laura Smith

Gabor Veres

Siang Chin

Phil Tinmouth

Janice Chen

Lucas Harrington

Elaine Sun

The Research and Development team at Mammoth Biosciences focuses on discovering and developing novel CRISPR systems to expand the company's next-generation genomics platform. This team conducts cutting-edge research to enhance diagnostics and genome editing applications, collaborating across various projects in life science research, healthcare, agriculture, and biodefense. Their work involves extensive experimentation, protein engineering, and automation to create advanced and accessible CRISPR-based solutions for improving disease detection and genetic manipulation.

Research and Development

Leadership Team

Legal and Corporate Governance

Research and Development

About

Team members

Other teams at Mammoth Biosciences

Leadership Team

Legal and Corporate Governance